Revenue Showdown: Bausch Health Companies Inc. vs Arrowhead Pharmaceuticals, Inc.

Pharma Giants: Bausch vs. Arrowhead Revenue Battle

__timestampArrowhead Pharmaceuticals, Inc.Bausch Health Companies Inc.
Wednesday, January 1, 20141750008263500000
Thursday, January 1, 201538200010498800000
Friday, January 1, 20161583339674000000
Sunday, January 1, 2017314077098724000000
Monday, January 1, 2018161423218380000000
Tuesday, January 1, 20191687955778601000000
Wednesday, January 1, 2020879920668027000000
Friday, January 1, 20211382870008434000000
Saturday, January 1, 20222432310008124000000
Sunday, January 1, 20232407350008757000000
Monday, January 1, 20243551000
Loading chart...

Igniting the spark of knowledge

Revenue Showdown: A Tale of Two Companies

In the dynamic world of pharmaceuticals, Bausch Health Companies Inc. and Arrowhead Pharmaceuticals, Inc. have carved distinct paths over the past decade. Bausch Health, with its robust revenue stream, consistently reported figures exceeding $8 billion annually from 2014 to 2023, peaking in 2015 with a staggering $10.5 billion. In contrast, Arrowhead Pharmaceuticals, a smaller player, has shown remarkable growth, with revenue surging from a modest $175,000 in 2014 to over $240 million by 2023, marking an impressive increase of over 137,000%.

While Bausch Health's revenue remained relatively stable, Arrowhead's trajectory highlights its aggressive expansion and innovation in the biotech sector. However, data for 2024 is incomplete, leaving room for speculation on future trends. This revenue showdown underscores the diverse strategies and market positions of these two industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025